Danielle Brill
Stock Analyst at Truist Securities
(3.92)
# 589
Out of 5,067 analysts
92
Total ratings
47.5%
Success rate
11.98%
Average return
Main Sectors:
Stocks Rated by Danielle Brill
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PVLA Palvella Therapeutics | Maintains: Buy | $80 → $105 | $98.03 | +7.11% | 3 | Nov 10, 2025 | |
| IRON Disc Medicine | Maintains: Buy | $86 → $114 | $94.11 | +21.13% | 7 | Nov 10, 2025 | |
| NBIX Neurocrine Biosciences | Reiterates: Buy | $165 → $172 | $141.25 | +21.77% | 7 | Oct 30, 2025 | |
| BBIO BridgeBio Pharma | Reiterates: Buy | $66 → $80 | $70.99 | +12.69% | 2 | Oct 30, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $459 → $535 | $434.23 | +23.21% | 2 | Oct 17, 2025 | |
| IMVT Immunovant | Initiates: Hold | $16 | $23.32 | -31.39% | 5 | Oct 14, 2025 | |
| UPB Upstream Bio | Initiates: Buy | $47 | $26.05 | +80.42% | 1 | Oct 14, 2025 | |
| DNTH Dianthus Therapeutics | Initiates: Buy | $56 | $43.68 | +28.21% | 1 | Oct 14, 2025 | |
| VRTX Vertex Pharmaceuticals | Initiates: Market Perform | n/a | $424.00 | - | 3 | Sep 3, 2025 | |
| HRMY Harmony Biosciences Holdings | Initiates: Buy | $48 | $35.27 | +36.09% | 8 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $64 | $19.66 | +225.53% | 2 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $29.37 | +2.15% | 1 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $21.41 | +12.10% | 1 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Strong Buy | $20 → $52 | $27.78 | +87.19% | 6 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $18.93 | - | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $79 | $55.50 | +42.34% | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $18 | $12.23 | +47.18% | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $150 | $18.91 | +693.23% | 3 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $176.82 | - | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Strong Buy | $605 | $907.42 | -33.33% | 7 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $23.90 | - | 5 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $50 | $42.05 | +18.91% | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $51 | $26.49 | +92.53% | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $180 → $100 | $8.56 | +1,068.22% | 5 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $79.83 | - | 9 | Sep 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $8.61 | - | 5 | Jun 27, 2023 |
Palvella Therapeutics
Nov 10, 2025
Maintains: Buy
Price Target: $80 → $105
Current: $98.03
Upside: +7.11%
Disc Medicine
Nov 10, 2025
Maintains: Buy
Price Target: $86 → $114
Current: $94.11
Upside: +21.13%
Neurocrine Biosciences
Oct 30, 2025
Reiterates: Buy
Price Target: $165 → $172
Current: $141.25
Upside: +21.77%
BridgeBio Pharma
Oct 30, 2025
Reiterates: Buy
Price Target: $66 → $80
Current: $70.99
Upside: +12.69%
Alnylam Pharmaceuticals
Oct 17, 2025
Maintains: Buy
Price Target: $459 → $535
Current: $434.23
Upside: +23.21%
Immunovant
Oct 14, 2025
Initiates: Hold
Price Target: $16
Current: $23.32
Upside: -31.39%
Upstream Bio
Oct 14, 2025
Initiates: Buy
Price Target: $47
Current: $26.05
Upside: +80.42%
Dianthus Therapeutics
Oct 14, 2025
Initiates: Buy
Price Target: $56
Current: $43.68
Upside: +28.21%
Vertex Pharmaceuticals
Sep 3, 2025
Initiates: Market Perform
Price Target: n/a
Current: $424.00
Upside: -
Harmony Biosciences Holdings
Jul 21, 2025
Initiates: Buy
Price Target: $48
Current: $35.27
Upside: +36.09%
Jul 21, 2025
Initiates: Buy
Price Target: $64
Current: $19.66
Upside: +225.53%
Jul 21, 2025
Initiates: Buy
Price Target: $30
Current: $29.37
Upside: +2.15%
Jul 21, 2025
Initiates: Buy
Price Target: $24
Current: $21.41
Upside: +12.10%
Dec 10, 2024
Upgrades: Strong Buy
Price Target: $20 → $52
Current: $27.78
Upside: +87.19%
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $18.93
Upside: -
Oct 10, 2024
Reinstates: Outperform
Price Target: $79
Current: $55.50
Upside: +42.34%
Oct 10, 2024
Reinstates: Outperform
Price Target: $18
Current: $12.23
Upside: +47.18%
Oct 10, 2024
Reinstates: Outperform
Price Target: $150
Current: $18.91
Upside: +693.23%
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $176.82
Upside: -
Oct 10, 2024
Reinstates: Strong Buy
Price Target: $605
Current: $907.42
Upside: -33.33%
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $23.90
Upside: -
Oct 10, 2024
Reinstates: Outperform
Price Target: $50
Current: $42.05
Upside: +18.91%
Oct 10, 2024
Reinstates: Outperform
Price Target: $51
Current: $26.49
Upside: +92.53%
Nov 14, 2023
Maintains: Outperform
Price Target: $180 → $100
Current: $8.56
Upside: +1,068.22%
Sep 18, 2023
Downgrades: Underperform
Price Target: n/a
Current: $79.83
Upside: -
Jun 27, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $8.61
Upside: -